Breaking News, Collaborations & Alliances

Alteogen, Daiichi Sankyo Partner on Subcutaneous ENHERTU

Daiichi Sankyo to develop subcutaneous ENHERTU using Alteogen's hyaluronidase technology.

Author Image

By: Charlie Sternberg

Associate Editor

Alteogen Inc. has entered into an exclusive license agreement with Daiichi Sankyo under which Daiichi Sankyo will acquire worldwide rights to use ALT-B4, Alteogen’s novel hyaluronidase utilizing Hybrozyme Technology, to develop and commercialize a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.   Alteogen will receive an upfront payment an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters